REMARKS

Applicants hereby submit that the enclosures fulfill the requirements under 37 C.F.R. §1.821-1.825. The amendments in the specification merely insert the paper copy of the Sequence Listing and sequence identifiers in the specification. No new matter has been added.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment.

Please apply any charges or credits to Deposit Account No. 06-1050, referencing attorney docket no. 11752-002001.

Respectfully submitted,

Date: 1-15-02

Y. Rocky Tsao

Y. Rocky Tsao
Reg. No. 34,053

Fish & Richardson P.C.
225 Franklin Street
Boston, Massachusetts 02110-2804
Telephone: (617) 542-5070
Facsimile: (617) 542-8906

20373655.doc

"Version With Markings to Show Changes Made"

In the specification:

Paragraph beginning at page 1, line 11, has been amended as follows:

Amylin is a 37-amino acid peptide cosecreted with insulin from the beta cells of the pancreatic islets. It was first reported by Cooper *et al* in Proceedings of the National Academy of Sciences, USA 84, 8628 (1987) and is the subject of European Patent 289287. Amylin has the following peptide sequence:

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-
1 5 10
Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Ser-Ser-
11 15 20
Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-
21 25 30
Asn-Val-Gly-Ser-Asn-Thr-Tyr (SEQ ID NO:1)
31 35

Paragraph beginning at page 4, line 1, has been amended as follows:

Other aspects include:

the use of amylin or an analog thereof in the preparation of a medicament for effecting chondrocyte proliferation;

the use of adrenomedullin or an analog thereof in the preparation of a medicament for effecting chondrocyte proliferation;

the use of a ligand which binds to and activates the receptor to which amylin and/or adrenomedullin binds (preferably the adrenomedullin receptor) in the preparation of a medicament for effecting chondrocyte proliferation;

the use of an amylin agonist in the preparation of a medicament for effecting chondrocyte proliferation;

the use of an adrenomedullin agonist in the preparation of a medicament for effecting chondrocyte proliferation;

the use of amylin-(1-8) (SEQ ID NO:2) in the preparation of a medicament for effecting chondrocyte proliferation; and

the use of adrenomedullin-(27-52) (SEQ ID NO:3) in the preparation of a medicament for effecting chondrocyte proliferation.

In the claims:

Claims 11, 22, 30, 33, 37, and 40 have been amended as follows:

11. (Amended) A method according to claim 10 wherein said amylin analog is amylin-(1-8) (SEQ ID NO:2).

22. (Twice Amended) A method according to claim 17 wherein said adrenomedullin analog is adrenomedullin-(27-52) (SEQ ID NO:3).

30. (Amended) A method according to claim 29 wherein the amylin analog is amylin-(1-8) (SEQ ID NO:2).

33. (Amended) A method according to claim 32 wherein the adrenomedullin analog is adrenomedullin-(27-52) (SEQ ID NO:3).

37. (Amended) A method according to claim 36 wherein the amylin analog is amylin-1-8 (SEQ ID NO:2).

40. (Amended) A method according to claim 39 wherein the adrenomedullin analog is adrenomedullin-27-52 (SEQ ID NO:3).